Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Review: Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes A new review article published in the journal Acta Pharmaceutica Sinica B summarizes advancements in drug delivery systems for three main glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are recommended for selected patients with obesity or type 2 diabetes, depending on indication, comorbidities, and treatment goals
Consistent reputation: Check online forums and communities for feedback about supplier quality and service
Cell 55 , 552565 (2014)
Candidates typically have BMI 27 with weight-related comorbidities or BMI 30, no personal/family history of medullary thyroid cancer, and no contraindications to GLP-1 therapy
US$ 29.75
US$ 25.89
US$ 21.88
US$ 29.10
